CAPLACIZUMAB (kap la SIZ ue mab) treats acquired thrombotic thrombocytopenic purpura (aTTP), a condition that causes blood clots and low levels of platelets in the body. It works by preventing blood cells (platelets) from clumping together to form a clot. It is a monoclonal antibody.


There is no lifestyle interaction information available for this medication.